STI571联合化疗治疗c-kit突变型SCLC疗效与安全性分析  

Analysis on effects and safety of STI571 combined with chemotherapy in treatment of c-kit mutant SCLC

作　　者：刘湘冬 谢卫民 李伟[1] Liu Xiangdong;Xie Weimin;Li Wei(Department of Oncology,Hospital 169 of PLA,Hengyang,Hunan,421002,China)

机构地区：[1]解放军169医院肿瘤内科,湖南衡阳421002

出　　处：《西南国防医药》2018年第12期1187-1189,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的分析伊马替尼(STI571)联合同步化疗治疗c-kit突变型小细胞肺癌(SCLC)的疗效与安全性。方法对135例c-kit突变型SCLC患者根据基因突变类型分为9号外显子突变型(34例)与11号外显子突变型(101例),将患者随机分为治疗组与对照组,其中治疗组68例采用口服STI571联合化疗治疗,对照组67例仅采用化疗治疗,根据治疗时间的不同分为Ⅰ期与Ⅱ期治疗,比较两组Ⅰ期与Ⅱ期的治疗有效率和不良反应。结果Ⅰ期治疗结束后,治疗组的总有效率(ORR)显著优于对照组(P <0.05),其中治疗组中11号外显子突变组的ORR显著优于对照组(P <0.05),而两组9号外显子突变组的ORR无显著差异(P> 0.05)。Ⅱ期治疗结束后,治疗组的ORR更加显著优于对照组(P <0.01),治疗组中9号与11号外显子突变组的ORR均显著优于对照组(P <0.05)。治疗期间,治疗组肌肉关节痛发生率显著高于对照组(P <0.05),两组在其他不良反应发生率及严重程度比较无显著差异(P> 0.05)。结论该联合治疗方案较单一化疗具有更好的近期疗效,临床治疗效果良好,且毒副反应较轻,可以作为一种针对c-kit突变型SCLC的有效治疗方案。Objective To analyze the effects of safety of imatinib(STI571) combined with chemotherapy in the treatment of c-kit mutant small cell lung cancer(SCLC). Methods A total of 135 patients with c-kit mutant SCLC were selected according to the types of gene mutation, including 34 ones with exon 9 mutations and 101 ones with exon 11 mutations, and randomly divided into a treatment group(n=68) and a control group(n=67). The treatment group was treated with oral administration of STI571 combined with chemotherapy. The control group was treated with chemotherapy only. The treatment was divided into Stage Ⅰand StageⅡ according to different treatment periods. The overall response rate(ORR) and adverse reactions were compared between StageⅠ and StageⅡ.Results After Stage Ⅰ treatment, the ORR in the treatment group was significantly higher than that in the control group(P < 0.05);the ORR in the exon 11 mutation subgroup in the treatment group was significantly higher than that in the control group(P < 0.05);there was no significant difference in the ORR in the exon 9 mutation subgroup between the two groups(P > 0.05). After Stage II treatment, the ORR in the treatment group was more significantly higher than that in the control group(P < 0.001); the ORR in the exon 9 mutation subgroup and the exon 11 mutation subgroup in the treatment group was significantly higher than that in the control group(P < 0.05). During the treatment, the incidence of muscle or joint pain in the treatment group was significantly higher than that in the control group(P < 0.05), and there was no significant difference in the incidence and severity of other adverse reactions between the two groups(P > 0.05). Conclusion This combination therapy has better short-term effects than single chemotherapy, has good clinical effects, causes minor toxic and side effects and can be used as an effective therapy for c-kit mutant SCLC.

关 键 词：伊马替尼 c-kit突变 小细胞肺癌 联合化疗 疗效 

分 类 号：R734[医药卫生—肿瘤]